A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT ID
NCT05098197
Phase
EARLY_PHASE1
Sponsor
Shanghai Juncell Therapeutics
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Tumor Infiltrating Lymphocyte
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age: 18 years to 75 years;
  • Histologically diagnosed as primary/relapsed/metastasized hepatobiliary cancer or pancreatic cancers;
  • Expected life-span more than 3 months;
  • Karnofsky≥60% or ECOG score 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →